An Update in Guillain-Barré Syndrome

Abstract EN

Guillain-Barré syndrome (GBS) was first described in 1916 (Guillain G, 1916) and is approaching its 100th anniversary.

Our knowledge of the syndrome has hugely expanded since that time.

Once originally considered to be only demyelinating in pathology we now recognise both axonal and demyelinating subtypes.

Numerous triggering or antecedent events including infections are recognised and GBS is considered an immunological response to these.

GBS is now considered to be a clinical syndrome of an acute inflammatory neuropathy encompassing a number of subtypes with evidence of different immunological mechanisms.

Some of these are clearly understood while others remain to be fully elucidated.

Complement fixing antibodies against peripheral nerve gangliosides alone and in combination are increasingly recognised as an important mechanism of nerve damage.

New antibodies against other nerve antigens such as neurofascin have been recently described.

Research databases have been set up to look at factors associated with prognosis and the influence of intravenous immunoglobulin (IvIg) pharmacokinetics in therapy.

Exciting new studies are in progress to examine a possible role for complement inhibition in the treatment of the syndrome.